Drug Trial Radar · NCT03512132
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 24, 2018
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire DijonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 30, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D). The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).
Conditions
- Type 1 Diabetes
Interventions
Blood samplesBiological
5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
Urine sampleBiological
Urine sample on an empty stomach
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability to induce cholesterol effluxTime frame: inclusion
- Nitric oxide synthesisTime frame: inclusion
- Anti-inflammatory effectTime frame: inclusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chu Dijon Bourogne
Dijon, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.